Year All2026202520242023202220212020201920182017201620152014 Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model September 25, 2024 Read More Abivax presents first-half 2024 financial results September 09, 2024 Read More Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone August 06, 2024 Read More Abivax Provides Operational and Key Program Update July 15, 2024 Read More Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting June 04, 2024 Read More Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 May 08, 2024 Read More Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents May 07, 2024 Read More Abivax publishes financial reports with the French and U.S. securities regulatory agencies April 05, 2024 Read More Abivax reports 2023 financial results and operational update April 02, 2024 Read More Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) February 13, 2024 Read More
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model September 25, 2024 Read More
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting June 04, 2024 Read More
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 May 08, 2024 Read More
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents May 07, 2024 Read More
Abivax publishes financial reports with the French and U.S. securities regulatory agencies April 05, 2024 Read More
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) February 13, 2024 Read More
